News
A Phase 1, First-in-Human Study of CT-95, a Mesothelin-Directed Bispecific T Cell Engager (TCE) in Subjects with Advanced Solid Tumors
Rodriguez Rivera et al.
Society for Immunotherapy of Cancer (SITC) I Annual Meeting I Abstract 536 I November 7-9, 2025
CT-202: a Dual pH-dependent Nectin-4xCD3 Bispecific T Cell Engager
Stanley A. Roberts, Kelly Byrnes-Blake, Heather Ansorge, Eric Butz
Society for Immunotherapy of Cancer (SITC) I Annual Meeting I Abstract 963 I November 7-9, 2025
A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors
Roisin E. O’Cearbhaill et al.
American Society of Clinical Oncology I Annual Meeting I Abstract TPS2685 I May 30-June 3, 2025